



IFW

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 28, 2005.*

*Trudi Thompson*

Trudi Thompson

Applicant : Joan S. Steffan, et al. Confirmation No. 7728  
Application No. : 10/789,518  
Filed : February 27, 2004  
Title : METHODS AND REAGENTS FOR REDUCING POLYGLUTAMINE  
TOXICITY  
  
Grp./Div. : 1614  
Examiner : Unassigned  
  
Docket No. : 52058/WPC/R2682  
Customer No. : 23363

**INFORMATION DISCLOSURE STATEMENT  
37 CFR § 1.97(b)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Post Office Box 7068  
Pasadena, CA 91109-7068  
January 28, 2005

Commissioner:

In compliance with the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, and in accordance with the provisions in the Manual of Patent Examining Procedure §§ 609 and 707.05(b), enclosed is FORM PTO/SB/08A/B listing the references that are known to applicant. Copies of each of the listed "Other Documents" references are enclosed. This filing is timely because it is made during one of the periods described in 37 CFR § 1.97(b).

It is respectfully requested that the listed references be considered in the examination of this application and identified on the list of references cited on the patent issuing for this application. Applicant also requests that an initialed copy of FORM PTO/SB/08A/B be entered

**Application No. 10/789,518**

in the application file and returned to applicant with the next communication from the Office in accordance with MPEP § 609.

Respectfully submitted,

CHRISTIE, PARKER & HALE, LLP

By Cynthia A. Bonner  
Cynthia A. Bonner  
Reg. No. 44,548  
626/795-9900


CAB/tt

Enclosures: PTO/SB/08A/B, w/references

**INFORMATION DISCLOSURE**

**STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
Application Number	10/789,518
Filing Date	February 27, 2004
Applicant(s)	Joan S. Steffan
Group Art Unit	1614
Examiner Name	Unassigned

**U.S. PATENT DOCUMENTS**

EXAMINER INITIALS	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (If Known)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE
		6,087,367	07/11/2000	Breslow et al.
		5,773,474	06/30/1998	Breslow et al.
		5,840,960	11/24/1998	Marks et al.
		5,932,616	08/03/1999	Breslow et al.
		5,700,811	12/23/1997	Breslow et al.
		5,668,179	09/16/1997	Breslow et al.
		5,608,108	03/04/1997	Marks et al.
		5,369,108	11/29/1994	Breslow et al.
		5,330,744	07/19/1994	Pontremoli et al.
		5,175,191	12/29/1992	Marks et al.

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS	Cite No. <sup>1</sup>	<u>Foreign Patent Document</u> Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	<sup>6</sup> (✓)

**OTHER DOCUMENTS**

EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		BATES et al., "Polyglutamine Expansion and Huntington's Disease", Biochemical Society Transactions, February 1998, 5 pages
		BATES et al., "Transgenic Models of Huntington's Disease", Human Molecular Genetics, Vol. 6, No. 10, 1997, Review, pp. 1633-1637
		CHAN et al., "Genetic Modulation of Polyglutamine Toxicity By Protein Conjugation Pathways In <i>Drosophila</i> ", Human Molecular Genetics, Vol. 11, No. 23, 2002, pp. 2895-2904
		GOTTLICHER et al., "Valproic Acid Defines A Novel Class of HDAC Inhibitors Inducing Differentiation Of Transformed Cells", The EMBO Journal, Vol. 20, No. 24, 2001, pp. 6969-6978

EXAMINER SIGNATURE	DATE CONSIDERED
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		LEONI et al., "The Antitumor Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Exhibits Antiinflammatory Properties Via Suppression Of Cytokines", PNAS, Vol. 99, No. 5, March 5, 2002, pp. 2995-3000
		LEVY et al., "Gamma-Hydroxybutyrate In The Treatment Of Schizophrenia", Psychiatry Research, Vol. 9, 1983, pp. 1-8
		MANGIARINI et al., "Instability Of Highly Expanded CAG Repeats In Mice Transgenic For The Huntington's Disease Mutation", Nature Genetics, Vol. 15, February 1997, pp. 197-200
		MCCAMPBELL et al., "Histone Deacetylase Inhibitors Reduce Polyglutamine Toxicity", PNAS, Vol. 98, No. 26, December 18, 2001, pp. 15179-15184
		ROSS et al., "SUMO-1 Modification Represses Sp3 Transcriptional Activation And Modulates Its Subnuclear Localization", Molecular Cell, October 1, 2002, 18 pgs.
		SARATIKOV et al., "Action Of Lithium Hydroxybutyrate On Electroencephalographic Effects Of Amphetamine", Bulletin of Experimental Biology and Medicine (English Translation 1982, rec'd 1983), pp. 907-910, Cover pg. (1)
		STEFFAN et al., "Histone Deacetylase Inhibitors Arrest Polyglutamine-Dependent Neurodegeneration in <i>Drosophila</i> ", Nature, Vol. 413, October 18, 2001, pp. 739-743
		STEFFAN et al., "The Huntington's Disease Protein Interacts With p53 And CREB-Binding Protein And Represses Transcription", PNAS, Vol. 97, No. 12, June 6, 2000, pp. 6763-6768
		XIRODIMAS et al., "P14ARF Promotes Accumulation Of SUMO-1 Conjugated (H)Mdm2", FEBS Letters, Vol. 528, 2002, pp. 207-211
		ZOGHBI et al., "Glutamine Repeats And Neurodegeneration", Annual Rev. Neurosci., Vol. 23, 2000, pp. 217-247
		ZUCCATO et al., "Huntingtin Interacts With REST/NRSF To Modulate The Transcription Of NRSE-Controlled Neuronal Genes", Nature Genetics, Vol. 35, No. 1, September 2003, pp. 76-83
		ZHONG et al., "The Transcriptional Role Of PML And The Nuclear Body", Nature Cell Biology, Vol. 2, May 2000, pp. E85-E90
		ZHONG et al., "Role Of SUMO-1-Modified PML In Nuclear Body Formation", Blood, Vol. 95, No. 9, May 1, 2000, pp. 2748-2753

EXAMINER SIGNATURE		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		YASUDA et al., "Triggering Of Neuronal Cell Death By Accumulation Of Activated SEK1 On Nuclear Polyglutamine Aggregations In PML Bodies", Genes to Cells, Vol. 4, 1999, pp. 743-756
		YANG et al. "Aggregated Polyglutamine Peptides Delivered To Nuclei Are Toxic To Mammalian Cells", Human Molecular Genetics, Vol. 11, No. 23, 2002, pp. 2905-2917
		YAMADA et al., "Interaction Between Neuronal Intranuclear Inclusions And Promyelocytic Leukemia Protein Nuclear And Coiled Bodies In CAG Repeat Diseases", American Journal of Pathology, Vol. 159, No. 5, November 2001, pp. 1785-1795
		SIPIONE et al., "Early Transcriptional Profiles In Huntingtin-Inducible Striatal Cells By Microarray Analyses", Human Molecular Genetics, Vol. 11, No. 17, 2002, pp. 1953-1965
		SEELER et al., "Common Properties Of Nuclear Body Protein SP100 And TIF1α Chromatin Factor: Role Of SUMO Modification", Molecular and Cellular Biology, Vol. 21, No. 10, May 2001, pp. 3314-3324
		WYTTEBACH et al., "Polyglutamine Expansions Cause Decreased CRE-Mediated Transcription And Early Gene Expression Changes Prior To Cell Death In An Inducible Cell Model Of Huntington's Disease", Human Molecular Genetics, Vol. 10, No. 17, 2001, pp. 1829-1845
		WYTTEBACH et al., "Effects Of Heat Shock, Heat Shock Protein 40 (HDJ-2), And Proteasome Inhibition On Protein Aggregation in Cellular Models of Huntington's Disease", PNAS, Vol. 97, No. 6, March 14, 2000, pp. 2898-2903
		WOOD et al., "Atrophin-1, The Dentato-Rubral And Pallido-Luysian Atrophy Gene Product, Interacts With ETO/MTG8 In The Nuclear Matrix And Represses Transcription", The Journal of Cell Biology, Vol. 150, No. 5, September 4, 2000, pp. 939-948
		SAUDOU et al., "Huntingtin Acts In The Nucleus To Induce Apoptosis But Death Does Not Correlate With The Formation Of Intranuclear Inclusions", Cell, Vol. 95, October 2, 1998, pp. 55-66
		WILSON et al., "Minireview: Intracellular Targeting Of Proteins by Sumoylation", Experimental Cell Research, No. 271, 2001, pp. 57-65
		SÁNCHEZ et al., "Pivotal Role Of Oligomerization In Expanded Polyglutamine Neurodegenerative Disorders", Nature, Vol. 421, January 23, 2003, pp. 373-379
		SACHDEV et al., "PIASy, A Nuclear Matrix-Associated SUMO E3 Ligase, Represses LEF1 Activity By Sequestration Into Nuclear Bodies", Genes and Development, Vol. 15, 2001, pp 3088-3103

EXAMINER SIGNATURE	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		WAEALTER et al., "Accumulation Of Mutant Huntingtin Fragments In Aggresome-Like Inclusion Bodies As A Result of Insufficient Protein Degradation", Molecular Biology of the Cell, Vol. 12, May 2001, pp. 1393-1407
		VERGER et al., "Modification With SUMO", EMBO Reports, Vol. 4, No. 2, 2003, pp. 137-142
		VENOT et al., "The Requirement For The p53 Proline-Rich Functional Domain For Mediation Of Apoptosis Is Correlated With Specific <i>PIG3</i> Gene Transactivation And With Transcriptional Repression", The EMBO Journal, Vol. 17, No. 16, 1998, pp. 4668-4679
		UESATO et al, "Novel Histone Deacetylase Inhibitors: <i>N</i> -Hydroxycarboxamides Possessing A Terminal Bicyclic Aryl Group", Bioorganic & Medicinal Chemistry Letters, Vol. 12, 2002, pp. 1347-1349
		UEKAMA et al., "Cyclodextrin Drug Carrier System", Chem. Rev., Vol. 98, 1998, pp. 2045-2076
		UEDA et al., "Enhanced SUMOylation In Polyglutamine Diseases", Biochemical and Biophysical Research Communications, Vol. 293, 2002, pp. 307-313
		MÜLLER et al., "Viral Immediate-Early Proteins Abrogate The Modification By SUMO-1 Of PML And Sp-100 Proteins, Correlating With Nuclear Body Disruption", Journal of Virology, Vol. 73, No. 6, June 1999, pp. 5137-5143
		TSUKAMOTO et al., "Visualization Of Gene Activity In Living Cells", Nature Cell Biology, Vol. 2, December 2000, pp. 871-878
		TSAI et al., "Parkin Facilitates The Elimination Of Expanded Polyglutamine Proteins And Leads To Preservation Of Proteasome Function", The Journal of Biological Chemistry, Vol. 278, No. 24, June 13, 2003, pp. 22044-22055
		TRUSHINA et al., "Microtubule Destabilization And Nuclear Entry Are Sequential Steps Leading To Toxicity In Huntington's Disease", PNAS, Vol. 100, No. 21, October 14, 2003, pp. 12171-12176
		TATHAM et al., "Polymeric Chains Of SUMO-2 And SUMO-3 Are Conjugated To Protein Substrates By SAE1/SAE2 And Ubc9", The Journal of Biological Chemistry, Vol. 276, No. 38, September 21, 2001, pp. 35368-35374
		TAKAHASHI et al., "Two Populations Of Neuronal Intranuclear Inclusions In SCA7 Differ In Size And Promyelocytic Leukaemia Protein Content", Brain, Vol. 125, 2002, pp. 1534-1543

EXAMINER SIGNATURE		DATE CONSIDERED	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.pto.gov](http://www.pto.gov) or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		MARKS et al., "Histone Deacetylase Inhibitors As New Cancer Drugs", Oncology, Vol. 13, 2001, pp. 477-483
		SZEBENYI et al., "Neuropathogenic Forms Of Huntingtin And Androgen Receptor Inhibit Fast Axonal Transport", Neuron, Vol. 40, September 25, 2003, pp. 41-52
		SUGARS et al., "Transcriptional Abnormalities In Huntington Disease", Trends in Genetics, Vol. 19, No. 5, May 2003, pp. 233-238
		SU et al., "Molecular Features Of Human Ubiquitin-Like SUMO Genes And Their Encoded Proteins", Gene, Vol. 296, 2002, pp. 65-73
		STRUDWICK et al., "Finding A Role For PML In APL Pathogenesis: A Critical Assessment Of Potential PML Activities", Leukemia, Vol. 16, 2002, pp. 1906-1917
		SMITH et al., "Inhibition Of Polyglutamine Aggregation In R6/2 HD Brain Slices-Complex Dose-Response Profiles", Neurobiology of Disease, Vol. 8, 2001, pp. 1017-1026
		SKINNER et al., "Ataxin-1 With An Expanded Glutamine Tract Alters Nuclear Matrix-Associated Structures", Nature, Vol. 389, October 30, 1997, pp. 971-974
		SITTLER et al., "SH3GL3 Associates With Huntingtin Exon 1 Protein And Promotes The Formation of Polyglu-Containing Protein Aggregates", Molecular Cell, Vol. 2, October 1998, pp. 427-436
		SIERADZAN et al., "Huntington's Disease Intranuclear Inclusions Contain Truncated, Ubiquitinated Huntingtin Protein", Experimental Neurology, Vol. 156, 1999, pp. 92-99
		SHIMOHATA et al., "Expanded Polyglutamine Stretches Interact With TAF <sub>II</sub> 130, Interfering With CREB-Dependent Transcription", Nature Genetics, Vol. 26, September 2000, pp. 29-36
		SHIH et al., "Identification of Septin-Interacting Proteins And Characterization Of The Smt3/SUMO-Conjugation System In <i>Drosophila</i> ", Journal of Cell Science, Vol. 115, No. 6, 2002, pp. 1259-1271
		SATHASIVAM et al., "Centrosome Disorganization In Fibroblast Cultures Derived From R6/2 Huntington's Disease (HD) Transgenic Mice And HD Patients", Human Molecular Genetics, Vol. 10, No. 21, 2001, pp. 2425-2435
		SALOMONI et al., "The Role Of PML In Tumor Suppression", Cell, Vol. 108, January 25, 2002, pp. 165-170

EXAMINER SIGNATURE		DATE CONSIDERED	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		SAITOH et al., "Perturbation Of SUMOlation Enzyme Ubc9 By Distinct Domain Within Nucleoporin Ran BP2/Nup358", The Journal of Biological Chemistry, Vol. 277, No. 7, February 15, 2002, pp. 4755-4763
		SAITOH et al., "Functional Heterogeneity Of Small Ubiquitin-Related Protein Modifiers SUMO-1 Versus SUMO-2/3", The Journal of Biological Chemistry, Vol. 275, No. 9, March 3, 2000, pp. 6252-6258
		RICHON et al., "Histone Deacetylase Inhibitor Selectively Induces p21 <sup>WAF1</sup> Expression And Gene-Associated Histone Acetylation", PNAS, Vol. 97, No. 18, August 29, 2000, pp. 10014-10019
		RICHON et al., "A Class Of Hybrid Polar Inducers Of Transformed Cell Differentiation Inhibits Histone Deacetylases", Cell Biology, Proc. Natl. Acad. Sci., USA, Vol. 95, March 1998, pp. 3003-3007
		RHO et al., "Age-Dependent Differences In Flurothyl Seizure Sensitivity In Mice Treated With A Ketogenic Diet", Epilepsy Research, Vol. 37, 1999, pp. 233-240
		REGAD et al., "Role And Fate Of PML Nuclear Bodies In Response To Interferon And Viral Infections", Oncogene, Vol. 20, 2001, pp. 7274-7286
		REDDY et al., "Recent Advances In Understanding The Pathogenesis Of Huntington's Disease", TINS, Vol. 22, No. 6, 1999, 248-255
		RANGASAMY et al., "SUMO-1 Modification Of Bovine Papillomavirus E1 Protein Is Required For Intracellular Accumulation", The Journal of Biological Chemistry, Vol. 275, No. 48, December 1, 2000, pp. 37999-38004
		POUNTNEY et al., "SUMO-1 Marks The Nuclear Inclusions In Familial Neuronal Intracellular Inclusion Disease", Experimental Neurology, Vol. 184, 2003, pp. 436-446
		POLLITT et al., "A Rapid Cellular FRET Assay Of Polyglutamine Aggregation Identifies A Novel Inhibitor", Neuron, Vol. 40, November 13, 2003, pp. 685-694
		PICHLER et al., "Ubiquitin-Related Modifier SUMO1 And Nucleocytoplasmic Transport", Traffic, Vol. 3, 2002, pp. 381-387
		PICHLER et al., "The Nucleoporin RanBP2 Has SUMO1 E3 Ligase Activity", Cell, Vol. 108, January 11, 2002, pp. 109-120

EXAMINER SIGNATURE	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		PHIEL et al., "Histone Deacetylase Is A Direct Target Of Valproic Acid, A Potent Anticonvulsant, Mood Stabilizer, and Teratogen", The Journal of Biological Chemistry, Vol. 276, No. 39, September 28, 2001, pp. 36734-36741
		PETERSEN et al., "Review: Recent Advances On The Pathogenesis Of Huntington's Disease", Experimental Neurology, Vol. 157, 1999, pp. 1-18
		PETERS et al., "Nuclear Targeting Of Mutant Huntingtin Increases Toxicity", Molecular and Cellular Neuroscience, Vol. 14, 1999, pp. 121-128
		PERUTZ, M., "Glutamine Repeats And Neurodegenerative Diseases: Molecular Aspects", TIBS, Vol. 24, February 1999, pp. 58-63
		PAULSON, H., "Human Genetics '99: Trinucleotide Repeats Protein Fate In Neurodegenerative Proteinopathies: Polyglutamine Diseases Join The (Mis)Fold", Am. J. Hum. Genet., Vol. 64, 1999, pp. 339-345
		PANDOLFI, P., "Histone Deacetylases And Transcriptional Therapy With Their Inhibitors", Cancer Chemother. Pharmacol, Vol. 48 (Suppl. 1), 2001, pp. S17-S19
		NUCIFORA, JR. et al., "Interference By Huntingtin And Atrophin-1 With CBP-Mediated Transcription Leading To Cellular Toxicity", Science, Vol. 291, March 23, 2001, pp. 2423-2428
		NICOT et al., "Distinct p300-Responsive Mechanisms Promote Caspase-Dependent Apoptosis By Human T-Cell Lymphotropic Virus Type 1 Tax Protein", Molecular and Cellular Biology, Vol. 20, No. 22, Nov. 2000, pp. 8580-8589
		NEUFELD et al., "A Genetic Screen To Identify Components Of The <i>sina</i> Signaling Pathway In Drosophila Eye Development", Genetics, Vol. 148, January 1998, pp. 277-286
		NEGOREV et al., "Cellular Proteins Localized At And Interacting Within ND10/PML Nuclear Bodies/PODs Suggest Functions Of A Nuclear Depot", Oncogene, Vol. 20, 2001, pp. 7234-7242
		MUSLIN et al., "14-3-3 Proteins: Regulation Of Subcellular Localization By Molecular Interference", Cellular Signalling, Vol. 12, 2000, pp. 703-709
		MURPHY et al., "Transcriptional Repression By Wild-Type p53 Utilizes Histone Deacetylases, Mediated By Interaction With mSin3a", Genes and Development, Vol. 13, 1999, pp. 2490-2501
		MULLER et al., "Sumo, Ubiquitin's Mysterious Cousin", Nature Reviews, Molecular Cell Biology, Vol. 2, March 2001, pp. 202-210

EXAMINER SIGNATURE	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		SCHERZINGER et al., "Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro And In Vivo", Cell, Vol. 90, August 8, 1997, pp. 549-558
		BRAND et al., "Targeted Gene Expression As A Means Of Altering Cell Fates And Generating Dominant Phenotypes", Development, Vol. 118, 1993, pp. 401-415
		STEFFAN et al., "Interaction Of TATA-Binding Protein With Upstream Activation Factor Is Required For Activated Transcription of Ribosomal DNA By RNA Polymerase I In <i>Saccharomyces cerevisiae</i> In Vivo", Molecular and Cellular Biology, Vol. 18, No. 7, July 1998, pp. 3752-3761
		SUHR et al., "High Level Transactivation By A Modified <i>Bombyx</i> Ecdysone Receptor In Mammalian Cells Without Exogenous Retinoid X Receptor", Proc. Natl. Acad. Sci. USA, Vol. 95, July 1998, pp. 7999-8004
		ADAMSON et al., "Epstein-Barr Virus Immediate-Early Protein BZLF1 Is SUMO-1 Modified And Disrupts Promyelocytic Leukemia Bodies", Journal of Virology, Vol. 75, No. 5, March 2001, pp. 2388-2399
		ALEFANTIS et al., "Characterization Of A Nuclear Export Signal Within the Human T Cell Leukemia Virus Type I Transactivator Protein Tax", The Journal of Biological Chemistry, Vol. 278, No. 24, June 13, 2003, pp. 21814-21822
		APOSTOL et al., "A Cell-Based Assay For Aggregation Inhibitors As Therapeutics of Polyglutamine-Repeat Disease And Validation In <i>Drosophila</i> ", PNAS, Vol. 100, No. 10, May 13, 2003, pp. 5950-5955
		KAZANTSEV et al., "Insoluble Detergent-Resistant Aggregates Form Between Pathological And Nonpathological Lengths Of Polyglutamine In Mammalian Cells", Proc. Natl. Acad. Sci. USA, Vol. 96, September 1999, pp. 11404-11409
		ROSS et al., "Polyglutamine Fibrillogenesis: The Pathway Unfolds", Proc. Natl. Acad. Sci. USA, Vol. 100, No. 1, Jan. 7, 2003, 8 pgs
		HUGHES et al., "Therapeutic Opportunities In Polyglutamine Disease", Nature Medicine, Vol. 7, No. 4, April 2001, pp. 419-423
		BORDEN, K., "Minireview: Pondering The Promyelocytic Leukemia Protein (PML) Puzzle: Possible Functions For PML Nuclear Bodies", Molecular and Cellular Biology, Vol. 22, No. 15, August 2002, pp. 5259-5269

EXAMINER SIGNATURE		DATE CONSIDERED	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.pto.gov](http://www.pto.gov) or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		MÜLLER et al., "c-Jun and p53 Activity Is Modulated By SUMO-1 Modification", The Journal of Biological Chemistry, Vol. 275, No. 18, May 5, 2000, pp. 13321-13329
		MULLER et al., "Conjugation With The Ubiquitin-Related Modifier SUMO-1 Regulates The Partitioning Of PML Within The Nucleus", The EMBO Journal, Vol. 17, No. 1, 1998, pp. 61-70
		MITSUI et al., "Purification Of Polyglutamine Aggregates And Identification Of Elongation Factor-1 $\alpha$ And Heat Shock Protein 84 As Aggregate-Interacting Proteins", The Journal of Neuroscience, Vol. 22, No. 21, November 1, 2002, pp. 9267-9277
		MELCHIOR, F., "SUMO - Nonclassical Ubiquitin" Annu. Rev. Cell Dev. Biol., Vol. 16, 2000, pp. 591-626
		MCCAMPBELL et al., "Polyglutamine And CBP: Fatal Attraction?", Nature Medicine, Vol. 7, No. 5, May 2001, pp. 528-530
		MCCAMPBELL et al., "CREB-Binding Protein Sequestration By Expanded Polyglutamine", Human Molecular Genetics, Vol. 9, No. 14, 2000, pp. 2197-2202
		MARSH et al., "Expanded Polyglutamine Peptides Alone Are Intrinsically Cytotoxic And Cause Neurodegeneration In <i>Drosophila</i> ", Human Molecular Genetics, Vol. 9, No. 1, 2000, pp. 13-25
		LUTHI-CARTER et al., "Decreased Expression of Striatal Signaling Genes In A Mouse Model Of Huntington's Disease", Human Molecular Genetics, Vol. 9, No. 9, 2000, pp. 1259-1271
		TERASHIMA et al., "SUMO-1 Co-Localized With Mutant Atrophin-1 With Expanded Polyglutamines Accelerates Intranuclear Aggregation And Cell Death", NeuroReport, Vol. 13, No. 17, December 3, 2002, pp. 2359-2364
		LI et al., "Positive And Negative Regulation Of APP Amyloidogenesis By Sumoylation", PNAS, Vol. 100, No. 1, January 7, 2003, pp. 259-264
		LI et al., "Sequestration And Inhibition Of Daxx-Mediated Transcriptional Repression By PML", Molecular and Cellular Biology, Vol. 20, No. 5, March 2000, pp. 1784-1796
		MARKS et al., "Histone Deacetylase Inhibitors: Inducers Of Differentiation Or Apoptosis Of Transformed Cells", Journal of the National Cancer Institute, Vol. 92, No. 15, August 2, 2000, pp. 1210-1216

EXAMINER SIGNATURE		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="http://www.pto.gov">www.pto.gov</a> or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		MARGOLIS et al., "Expansion Explosion: New Clues To The Pathogenesis Of Repeat Expansion Neurodegenerative Diseases", Trends in Molecular Medicine, Vol.. 11, No. 7, November 2001, pp. 479-482
		MANGIARINI et al., "Exon 1 Of The <i>HD</i> Gene With An Expanded CAG Repeat Is Sufficient To Cause A Progressive Neurological Phenotype In Transgenic Mice", Cell, Vol. 87, November 1, 1996, pp. 493-506
		LUO et al., "Negative Control Of p53 By Sir2 $\alpha$ Promotes Cell Survival Under Stress", Cell, Vol. 107, October 19, 2001, pp. 137-148
		LIN et al., "SUMO-1/Ubc9 Promotes Nuclear Accumulation And Metabolic Stability Of Tumor Suppressor Smad4", The Journal of Biological Chemistry, Vol. 278, No. 33, August 15, 2003, pp. 31043-31048
		LIN et al., "Transcriptional Regulation In Acute Promyelocytic Leukemia", Oncogene, Vol. 20, 2001, pp. 7204-7215
		LI et al., "Interaction Of Huntington Disease Protein With Transcriptional Activator Sp1", Molecular and Cellular Biology, Vol. 22, No. 5, March 2002, pp. 1277-1287
		LEVINE, A., "p53, The Cellular Gatekeeper For Growth And Division", Cell, Vol. 88, February 7, 1997, pp. 323-331
		LANGLEY et al., "Human SIR2 Deacetylates p53 And Antagonizes PML/p53-Induced Cellular Senescence", The EMBO Journal, Vol. 21, No. 10, 2002, pp. 2383-2396
		LALLEMAND-BREITENBACH et al., "Role Of Promyelocytic Leukemia (PML) Sumolation In Nuclear Body Formation, 11S Proteasome Recruitment, and As <sub>2</sub> O <sub>3</sub> -Induced PML or PML/Retinoic Acid Receptor $\alpha$ Degradation", J. Exp. Med., Vol. 193, No. 12, June 18, 2001, pp. 1361-1371
		KRÄMER et al., "Histone Deacetylase As A Therapeutic Target", Trends in Endocrinology & Metabolism, Vol. 12, No. 7, September 2001, pp. 294-300
		HUGHES, R., "Polyglutamine Disease: Acetyltransferases Awry", Current Biology, Vol. 12, February 19, 2002, pp. R141-R143
		HUGHES et al., "Altered Transcription In Yeast Expressing Expanded Polyglutamine", PNAS, Vol. 98, No. 23, November 6, 2001, pp. 13201-13206

EXAMINER SIGNATURE		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		HOEGE et al., "RAD6-Dependent DNA Repair Is Linked To Modification Of PCNA By Ubiquitin And SUMO", Nature, Vol. 419, September 12, 2002, pp. 135-141
		KIRSH et al., "The SUMO E3 Ligase RanBP2 Promotes Modification Of The HDAC4 Deacetylase", The EMBO Journal, Vol. 21, No. 11, 2002, pp. 2682-2691
		KHOSHMAN et al., "Effects Of Intracellular Expression Of Anti-Huntingtin Antibodies Of Various Specificities On Mutant Huntingtin Aggregation And Toxicity", PNAS, Vol. 99, No. 2, January 22, 2002, pp. 1002-1007
		KEGEL et al., "Huntingtin Is Present In the Nucleus, Interacts With The Transcriptional Corepressor C-terminal Binding Protein, And Represses Transcription", The Journal of Biological Chemistry, Vol. 277, No. 9, March 1, 2002, pp. 7466-7476
		KAZANTSEV et al., "A Bivalent Huntingtin Binding Peptide Suppresses Polyglutamine Aggregation And Pathogenesis In <i>Drosophila</i> ", Nature Genetics, Vol. 30, April 2002, pp. 367-376
		KAYTOR et al., "Nuclear Localization Of The Spinocerebellar Ataxia Type 7 Protein, Ataxin-7", Human Molecular Genetics, Vol. 8, No. 9, 1999, pp. 1657-1664
		DONALDSON et al., "Ubiquitin-Mediated Sequestration Of Normal Cellular Proteins Into Polyglutamine Aggregates", PNAS. Vol. 100, No. 15, July 22, 2003, pp. 8892-8897
		KAYED et al., "Common Structure Of Soluble Amyloid Oligomers Implies Common Mechanism Of Pathogenesis", Science, Vol. 300, April 18, 2003, pp. 486-489
		KAO et al., "p53-Independent Induction Of Apoptosis By The HTLV-1 Tax Protein Following UV Irradiation", Virology, Vol. 291, 2001, pp. 292-298
		CUMMINGS et al., "Mutation Of The E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology In <i>SCA1</i> Mice", Neuron., Vol. 24, December 1999, pp. 879-892
		KAMITANI et al., "Identification Of Three Major Sentrinization Sites In PML", The Journal of Biological Chemistry, Vol. 273, No. 41, October 9, 1998, pp. 26675-26682
		KALCHMAN et al., "Huntingtin Is Ubiquitinated And Interacts With A Specific Ubiquitin-Conjugating Enzyme", The Journal of Biological Chemistry, Vol. 271, No. 32, August 9, 1996, pp. 19385-19394

EXAMINER SIGNATURE		DATE CONSIDERED	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.pto.gov](http://www.pto.gov) or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		BATES et al., "Symposium: Transgenic Models Of Neurodegeneration; Transgenic Mice In The Study Of Polyglutamine Repeat Expansion Diseases", Brain Pathology, Vol. 8, 1998, pp. 699-714
		KAHYO et al., "Involvement Of P1AS1 In The Sumoylation Of Tumor Suppressor p53", Molecular Cell, Vol. 8, September 2001, pp. 713-718
		ISHOV et al., "PML Is Critical For ND10 Formation And Recruits The PML-Interacting Protein Daxx To This Nuclear Structure When Modified By SUMO-1", The Journal of Cell Biology, Vol. 147, No. 2, October 18, 1999, pp. 221-233
		HOLBERT et al., "The Gln-Ala Repeat Transcriptional Activator CA150 Interacts With Huntingtin: Neuropathologic And Genetic Evidence For A Role In Huntington's Disease Pathogenesis", PNAS, Vol. 98, No. 4, February 13, 2001, pp. 1811-1816
		HOCKLY et al., "Suberoylanilide Hydroxamic Acid, A Histone Deacetylase Inhibitor, Ameliorates Motor Deficits In A Mouse Model Of Huntington's Disease", PNAS, Vol. 100, No. 4, February 18, 2003, pp. 2041-2046
		HOCKLY et al., "Environmental Enrichment Slows Disease Progression In R6/2 Huntington's Disease Mice", Ann. Neurol., Vol. 51, 2002, pp. 235-242
		HARROD et al., " Human Immunodeficiency Virus Type-1 Tat/Co-Activator Acetyltransferase Interactions Inhibit p53 <sup>Lys-320</sup> Acetylation And p53-Responsive Transcription", The Journal of Biological Chemistry, Vol. 278, No. 14, April 14, 2003, pp. 12310-12318
		KLEMENT et al., "Ataxin-1 Nuclear Localization And Aggregation: Role In Polyglutamine-Induced Disease In SCA1 Transgenic Mice", Cell, Vol. 95, October 2, 1998, pp. 41-53
		HARROD et al., "p300 And p300/cAMP-Responsive Element-Binding Protein Associated Factor Interact With Human T-Cell Lymphotropic Virus Type-1 Tax In A Multi-Histone Acetyltransferase/Activator-Enhancer Complex", The Journal of Biological Chemistry, Vol. 275, No. 16, April 21, 2000, pp. 11852-11857
		GUTEKUNST et al., "Nuclear And Neuropil Aggregates In Huntington's Disease: Relationship To Neuropathology", The Journal of Neuroscience, Vol. 19, No. 7, April 1, 1999, pp. 2522-2534
		GUNAWARDENA et al., "Disruption Of Axonal Transport By Loss Of Huntingtin Or Expression Of Pathogenic PolyQ Proteins In <i>Drosophila</i> ", Neuron, Vol. 40, September 25, 2003, pp. 25-40
		GUIDOTTI et al., "Decrease In Reelin And Glutamic Acid Decarboxylase <sub>67</sub> (GAD <sub>67</sub> ) Expression In Schizophrenia And Bipolar Disorder", Arch. Gen. Psychiatry, Vol. 57, Nov. 2000, pp. 1061-1069

EXAMINER SIGNATURE		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		GU et al., "Synergistic Activation Of Transcription By CBP And p53", Nature, Vol. 387, June 19, 1997, pp. 819-823
		GLICKMAN et al., "The Ubiquitin-Proteasome Proteolytic Pathway: Destruction For The Sake Of Construction", Physiol. Rev. Vol. 82, 2002, pp. 373-428
		GIRDWOOD et al., "p300 Transcriptional Repression Is Mediated By SUMO Modification", Molecular Cell, Vol. 11, April 2003, pp. 1043-1054
		GERBER et al., "Transcriptional Activation Modulated By Homopolymeric Glutamine And Proline Stretches", Science, Vol. 263, February 11, 1994, pp. 808-811
		GALLIMORE et al., "Adenovirus E1A: Remodelling The Host Cell, A Life Or Death Experience", Oncogene, Vol. 20, 2001, pp. 7824-7835
		FUCHSOVA et al., "Nuclear DNA Helicase II Is Recruited To IFN- $\alpha$ -Activated Transcription Sites At PML Nuclear Bodies", The Journal of Cell Biology, Vol. 158, No. 3, August 5, 2002, pp. 463-473
		FINNIN et al., "Structures Of A Histone Deacetylase Homologue Bound To The TSA And SAHA Inhibitors", Nature, Vol. 401, September 9, 1999, pp. 188-193
		FERRANTE et al., "Histone Deacetylase Inhibition By Sodium Butyrate Chemotherapy Ameliorates The Neurodegenerative Phenotype In Huntington's Disease Mice", The Journal of Neuroscience, Vol. 23, No. 28, October 15, 2003, pp. 9418-9427
		FERRANTE et al., "Neuroprotective Effects Of Creatine In A Transgenic Mouse Model Of Huntington's Disease", The Journal of Neuroscience, Vol. 20, No. 12, June 15, 2000, pp. 4389-4397
		FERNANDEZ-FUNEZ et al., "Identification Of Genes That Modify Ataxin-1-Induced Neurodegeneration", Nature, Vol. 408, November 2, 2000, pp. 101-106
		FERBEYRE, G., "PML A Target Of Translocations In APL Is A Regulator Of Cellular Senescence", Leukemia, Vol. 16, 2002, pp. 1918-1926
		FABUNMI et al., "Interferon $\gamma$ Regulates Accumulation Of The Proteasome Activator PA28 And Immunoproteasomes At Nuclear PML Bodies", Journal of Cell Science, Vol. 114, December 11, 2000, pp. 29-36
		EVERETT, R., "DNA Viruses And Viral Proteins That Interact With PML Nuclear Bodies", Oncogene, Vol. 20, 2001, pp. 7266-7273

EXAMINER SIGNATURE	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	<b>Application Number</b>	<b>10/789,518</b>
	<b>Filing Date</b>	<b>February 27, 2004</b>
	<b>Applicant(s)</b>	<b>Joan S. Steffan</b>
	<b>Group Art Unit</b>	<b>1614</b>
	<b>Examiner Name</b>	<b>Unassigned</b>

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		EVERETT et al., "The Disruption Of ND10 During Herpes Simplex Virus Infection Correlates With The Vmw110- And Proteasome-Dependent Loss Of Several PML Isoforms", Journal of Virology, Vol. 72, No. 8, August 1998, pp. 6581-6591
		ESKIW et al., "Minireview/Minisynthese: The Promyelocytic Leukemia Nuclear Body: Sites Of Activity?", Biochem Cell Biol., Vol. 80, 2002, pp. 301-310
		ELLIS et al., "Expression Of <i>Drosophila</i> Glass Protein And Evidence For Negative Regulation Of Its Activity In Non-Neuronal Cells By Another DNA-Binding Protein", Development, Vol. 119, 1993, pp. 855-865
		EGO et al., "The Interaction of HTLV-1 Tax With HDAC1 Negatively Regulates The Viral Gene Expression", Oncogene, Vol. 21, 2002, pp. 7241-7246
		DUNAH et al., "Sp1 and TAFII130 Transcriptional Activity Disrupted In Early Huntington's Disease", Science, Vol. 296, June 21, 2002, pp. 2238-2243
		DIFIGLIA et al., "Aggregation Of Huntingtin In Neuronal Intranuclear Inclusions And Dystrophic Neurites In Brain", Science, Vol. 277, September 26, 1997, pp 1990-1993
		DESTERRO et al., "SUMO-1 Modification Of IκBα Inhibits NF-κB Activation", Molecular Cell, Vol. 2, August 1998, pp. 233-239
		DESJARDINS et al., "The Role Of Apoptosis In Neurodegenerative Diseases", Metabolic Brain Disease, Vol. 13, No. 2, 1998, pp 79-96
		DAVIES et al., "Formation Of Neuronal Intranuclear Inclusions Underlies The Neurological Dysfunction In Mice Transgenic For The HD Mutation", Cell, Vol. 90, August 8, 1997, pp. 537-548
		DAVID et al., "SUMO-1 Modification Of Histone Deacetylase 1 (HDAC1) Modulates Its Biological Activities", The Journal of Biological Chemistry, Vol. 277, No. 26, June 28, 2002, pp. 23658-23663
		CUMMINGS et al., "Chaperone Suppression Of Aggregation And Altered Subcellular Proteasome Localization Imply Protein Misfolding In SCA1", Nature Genetics, Vol. 19, June 1998, pp. 148-154
		CHIN et al., "Modulation Of Activity Of The Promoter Of The Human MDR1 Gene By Ras And p53", Science, New Series, Vol. 255, No. 5043, January 24, 1992, pp. 459-462, cover pg. (1)
		CHELBI-ALIX et al., "Herpes Virus Induced Proteasome-Dependent Degradation Of The Nuclear Bodies-Associated PML And Sp100 Proteins", Oncogene, Vol. 18, 1999, pp. 935-941

<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b>	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English Language Translation is attached.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	Application Number	10/789,518
	Filing Date	February 27, 2004
	Applicant(s)	Joan S. Steffan
	Group Art Unit	1614
	Examiner Name	Unassigned

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		CHAN et al., "Mechanisms Of Chaperone Suppression Of Polyglutamine Disease: Selectivity, Synergy And Modulation Of Protein Solubility In <i>Drosophila</i> ", Human Molecular Genetics, Vol. 9, No. 19, 2000, pp. 2811-2820
		CHAI et al., "Evidence For Proteasome Involvement In Polyglutamine Disease: Localization To Nuclear Inclusions In SCA3/MJD And Suppression Of Polyglutamine Aggregation <i>In Vitro</i> ", Human Molecular Genetics, Vol. 8, No. 4, 1999, pp. 673-682
		CHA, J., "Transcriptional Dysregulation In Huntington's Disease", TINS, Vol. 23, No. 9, 2000, pp. 387-392
		CATTANEO et al., "Loss Of Normal Huntingtin Function: New Developments In Huntington's Disease Research", Trends in Neurosciences, Vol. 24, No. 3, March 2001, pp. 182-188
		CARVALHO et al., "Targeting Of Adenovirus E1A And E4-ORF3 Proteins To Nuclear Matrix-Associated PML Bodies", The Journal of Cell Biology, Vol. 131, No. 1, October 1995, pp. 45-56
		CAO et al., "A Transcriptionally Active Complex of APP With Fe65 And Histone Acetyltransferase Tip60", Science, Vol. 293, July 6, 2001, pp. 115-120
		BUTLER et al., "Suberoylanilide Hydroxamic Acid, An Inhibitor Of Histone Deacetylase, Suppresses The Growth Of Prostate Cancer Cells <i>In Vitro And In Vivo</i> ", Cancer Research, Vol. 60, September 15, 2000, pp. 5165-5170
		BOUTELL et al., "Aberrant Interactions Of Transcriptional Repressor Proteins With The Huntington's Disease Gene Product, Huntingtin", Human Molecular Genetics, Vol. 8, No. 9, 1999, pp. 1647-1655
		BENCE et al., "Impairment Of The Ubiquitin-Proteasome System By Protein Aggregation", Science, Vol. 292, May 25, 2001, pp. 1552-1555
		BEDALOV et al., "Identification Of A Small Molecule Inhibitor Of Sir2p", PNAS, Vol. 98, No. 26, December 18, 2001, pp. 15113-15118
		BATES, G., "Huntingtin Aggregation And Toxicity In Huntington's Disease", The Lancet, Vol. 361, May 10, 2003, pp. 1642-1644
		AZIMI et al., "IL-15 Plays A Major Role In The Persistence Of Tax-Specific CD8 Cells in HAM/TSP Patients", PNAS, Vol. 98, No. 25, December 4, 2001, pp. 14559-14564

EXAMINER SIGNATURE	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.pto.gov or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>FORM PTO/SB/08A/B (10-01)</b> Substitute for PTO-1449A/B  <b>INFORMATION DISCLOSURE</b>  <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Attorney Docket Number</b>	<b>52058/WPC/R2682</b>
	<b>Application Number</b>	<b>10/789,518</b>
	<b>Filing Date</b>	<b>February 27, 2004</b>
	<b>Applicant(s)</b>	<b>Joan S. Steffan</b>
	<b>Group Art Unit</b>	<b>1614</b>
	<b>Examiner Name</b>	<b>Unassigned</b>

OTHER DOCUMENTS		
EXAMINER INITIALS	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		ARIUMI et al., "HTLV-1 Tax Oncoprotein Represses The p53-Mediated <i>Trans</i> -Activation Function Through Coactivator CBP Sequestration", <i>Oncogene</i> , Vol. 19, 2000, pp. 1491-1499
		STEFFAN et al., "Targeting Aggregation In The Development of Therapeutics For The Treatment Of Huntington's Disease And Other Polyglutamine Repeat Diseases", <i>Expert Opin. Ther. Targets</i> , Vol. 7, No. 2, 2003, pp. 201-213
		STEFFAN et al., "The Role Of TBP In rDNA Transcription By RNA Polymerase I In <i>Saccharomyces Cerevisiae</i> : TBP Is Required For Upstream Activation Factor-Dependent Recruitment Of Core Factor", <i>Genes and Development</i> , Vol. 10, July 1996, pp. 2551-2563

TXT IRV1080063.1-\*01/27/05 9:22 AM

<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b>	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="http://www.pto.gov">www.pto.gov</a> or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE